AI Summary
A safe and effective dendritic cell vaccine showed promising results in patients with high-risk multiple myeloma, improving their clinical outcomes following autologous stem cell transplant.
A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe and immunogenic and was associated with durable clinical responses in patients with high-risk multiple myeloma.